Cargando…
Role of prostacyclin in pulmonary hypertension
Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bloomsbury Qatar Foundation Journals
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355513/ https://www.ncbi.nlm.nih.gov/pubmed/25780793 http://dx.doi.org/10.5339/gcsp.2014.53 |
_version_ | 1782360870757597184 |
---|---|
author | Mitchell, Jane A. Ahmetaj-Shala, Blerina Kirkby, Nicholas S. Wright, William R. Mackenzie, Louise S. Reed, Daniel M. Mohamed, Nura |
author_facet | Mitchell, Jane A. Ahmetaj-Shala, Blerina Kirkby, Nicholas S. Wright, William R. Mackenzie, Louise S. Reed, Daniel M. Mohamed, Nura |
author_sort | Mitchell, Jane A. |
collection | PubMed |
description | Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since it's discovery in the 1970s concerted efforts have been made to make the best therapeutic utility of prostacyclin, particularly in the treatment of pulmonary arterial hypertension. This has centred on working out the detailed pharmacology of prostacyclin and then synthesising new molecules based on its structure that are more stable or more easily tolerated. In addition, newer molecules have been developed that are not analogues of prostacyclin but that target the receptors that prostacyclin activates. Prostacyclin and related drugs have without doubt revolutionised the treatment and management of pulmonary arterial hypertension but are seriously limited by side effects within the systemic circulation. With the dawn of nanomedicine and targeted drug or stem cell delivery systems it will, in the very near future, be possible to make new formulations of prostacyclin that can evade the systemic circulation allowing for safe delivery to the pulmonary vessels. In this way, the full therapeutic potential of prostacyclin can be realised opening the possibility that pulmonary arterial hypertension will become, if not curable, a chronic manageable disease that is no longer fatal. This review discusses these and other issues relating to prostacyclin and its use in pulmonary arterial hypertension. |
format | Online Article Text |
id | pubmed-4355513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Bloomsbury Qatar Foundation Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-43555132015-03-16 Role of prostacyclin in pulmonary hypertension Mitchell, Jane A. Ahmetaj-Shala, Blerina Kirkby, Nicholas S. Wright, William R. Mackenzie, Louise S. Reed, Daniel M. Mohamed, Nura Glob Cardiol Sci Pract Mechanisms of Disease Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since it's discovery in the 1970s concerted efforts have been made to make the best therapeutic utility of prostacyclin, particularly in the treatment of pulmonary arterial hypertension. This has centred on working out the detailed pharmacology of prostacyclin and then synthesising new molecules based on its structure that are more stable or more easily tolerated. In addition, newer molecules have been developed that are not analogues of prostacyclin but that target the receptors that prostacyclin activates. Prostacyclin and related drugs have without doubt revolutionised the treatment and management of pulmonary arterial hypertension but are seriously limited by side effects within the systemic circulation. With the dawn of nanomedicine and targeted drug or stem cell delivery systems it will, in the very near future, be possible to make new formulations of prostacyclin that can evade the systemic circulation allowing for safe delivery to the pulmonary vessels. In this way, the full therapeutic potential of prostacyclin can be realised opening the possibility that pulmonary arterial hypertension will become, if not curable, a chronic manageable disease that is no longer fatal. This review discusses these and other issues relating to prostacyclin and its use in pulmonary arterial hypertension. Bloomsbury Qatar Foundation Journals 2014-12-31 /pmc/articles/PMC4355513/ /pubmed/25780793 http://dx.doi.org/10.5339/gcsp.2014.53 Text en © 2014 Mitchell, Ahmetaj-Shala, Kirkby, Wright, Mackenzie, Reed, Mohamed, licensee Bloomsbury Qatar Foundation Journals. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Mechanisms of Disease Mitchell, Jane A. Ahmetaj-Shala, Blerina Kirkby, Nicholas S. Wright, William R. Mackenzie, Louise S. Reed, Daniel M. Mohamed, Nura Role of prostacyclin in pulmonary hypertension |
title | Role of prostacyclin in pulmonary hypertension |
title_full | Role of prostacyclin in pulmonary hypertension |
title_fullStr | Role of prostacyclin in pulmonary hypertension |
title_full_unstemmed | Role of prostacyclin in pulmonary hypertension |
title_short | Role of prostacyclin in pulmonary hypertension |
title_sort | role of prostacyclin in pulmonary hypertension |
topic | Mechanisms of Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355513/ https://www.ncbi.nlm.nih.gov/pubmed/25780793 http://dx.doi.org/10.5339/gcsp.2014.53 |
work_keys_str_mv | AT mitchelljanea roleofprostacyclininpulmonaryhypertension AT ahmetajshalablerina roleofprostacyclininpulmonaryhypertension AT kirkbynicholass roleofprostacyclininpulmonaryhypertension AT wrightwilliamr roleofprostacyclininpulmonaryhypertension AT mackenzielouises roleofprostacyclininpulmonaryhypertension AT reeddanielm roleofprostacyclininpulmonaryhypertension AT mohamednura roleofprostacyclininpulmonaryhypertension |